Article
The p53-MDM2 interaction in a cancer-prone family, and the identification of a novel therapeutic target.
Acta oncologica (Stockholm, Sweden) - 1 Jan 1996
Picksley S M, Spicer J F, Barnes D M, Lane D P
Abstract excerpt
One approach to developing novel anti-cancer agents is to identify and characterise targets that directly regulate cell growth and are dysfunctional in the disease state. One such target is the interaction between the p53 tumour suppressor and the oncogene product of the murine double minute gene, MDM2. MDM2 is known to bind wild-type p53 and block the transcriptional activation of p53-dependent genes. We have...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.